Group sequential clinical trials for longitudinal data with analyses using summary statistics

Statistics in Medicine

Volumn 24, Issue 16, 2005, Pages 2457-2475

  Kittelson, John M ^a   Sharples, Katrina ^b   Emerson, Scott S ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Area under curve; Clinical trial; Longitudinal endpoint; Mixed effects model; Software

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ARTERY DISEASE; ARTICLE; CALCULATION; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER PROGRAM; DATA ANALYSIS; DECISION MAKING; FOLLOW UP; HUMAN; INFORMATION PROCESSING; METHODOLOGY; OUTCOMES RESEARCH; STATISTICAL ANALYSIS;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LINEAR MODELS; LONGITUDINAL STUDIES; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS; SOFTWARE; WALKING;

EID: 23244442858     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2127     Document Type: Article

References (31)

1. Shih WJ, Quan H. Planning and analysis of repeated measures at key time points in clinical trials sponsored by pharmaceutical companies. Statistics in Medicine 1999; 18:961-973.
2. Ben-Josef E, Shamsa F, Forman JD. Predicting the outcome of radiotherapy for prostate cancer. Cancer 1998; 82:1334-1342.
3. Molina L, Elosua R, Marrugat J, Pons S. Relation of maximum blood pressure during exercise and regular physical activity in normotensive men with left ventricular mass and hypertrophy. American Journal of Cardiology 1999; 84:890-893.
4. Laird NM, Want F. Estimating rates of change in randomized clinical trials. Controlled Clinical Trials 1990; 11:405-419.
5. Frison LJ, Pocock SJ. Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary measures. Statistics in Medicine 1997; 16:2855-2872.
6. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Statistics in Medicine 1992; 11:1685-1704.
7. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300:230-235.
8. Zackin R, Marschner IC, Anderson J, Cowles MK, DeGruttola V, Hammer S, Fischl M, Cotton D. HIV-1 RNA endpoints in HIV clinical trials: issues in interim monitoring and early stopping. Journal of Infectious Diseases 1998; 177:761-765.
9. Kittelson JM, Emerson SS. A unifying family of group sequential test designs. Biometrics 1999; 55:874-882.
10. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.
11. Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics 1988; 44:579-585.
12. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. Journal of the Royal Statistical Society, Series A, General 1994; 157:357-387.
13. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982; 38:963-974.
14. Lee JW, DeMets DL. Sequential comparison of changes with repeated measurements data. Journal of American Statistical Association 1991; 86:757-762.
15. Gange SJ, DeMets DL. Sequential monitoring of clinical trials with correlated responses. Biometrika 1996; 83:157-167.
16. Lee SJ, Kim K, Tsiatis AA. Repeated significance testing in longitudinal clinical trials. Biometrika 1996; 83: 779-789.
17. Jennison C, Tumbull BW. Group Sequential Methods with Application to Clinical Trials. Chapman & Hall/CRC: Boca Raton, 2000.
18. Little RJA, Rubin DB. Statistical Analysis with Missing Data. Wiley: New York, 1987.
19. Galbraith S, Marschner IC. Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes. Statistics in Medicine 2003; 22:1787-1805.
20. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Chapman & Hall/CRC: Boca Raton, 2002; 161-167.
21. Spiessens B, Lesaffre E, Verbeke G, Kim K, DeMets D. An overview of groups sequential methods in longitudinal clinical trials. Statistical Methods in Medical Research 2000; 9:497-515.
22. Simons M, Annes BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervina EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2 double-blind, randomized, controlled clinical trial. Circulation 2002; 105:788-793.
23. R project for statistical computing. http://www.r-project.org/
24. S+Seqtrial. Insightful Corporation. Seattle Washington. http://www.insightful.com/products/seqtrial/default.asp
25. East. Cytel Statistical Software. Cambridge, Massachusetts. http://www.cyte.com/East/Default.asp
26. Pest. Medical and Pharmaceutical Statistics Research Unit. University of Reading: Reading, U.K. http://www.rdg.ac.uk/mps/mps_home/software/software.htm
27. Emerson SS, Fleming TR. Parameter estimation following group sequential hypothesis testing. Biometrika 1990; 77:875-892.
28. Emerson SS, Fleming TR. Symmetric group sequential test designs. Biometrics 1989; 45:905-923.
29. Burington BE, Emerson SS. Flexible implementations of group sequential stopping rules using constrained boundaries. Biometrics 2003; 59:770-777.
30. Diggle PJ, Heagerty P, Liang KY, Zeger SL. Analysis of Longitudinal Data (2nd edn). Oxford University Press: New York, 2002; 319-326.
31. Gillen DL, Emerson SS. Information growth in a family of weighted logrank statistics under repeated analyses. Sequential Analysis 2005; 24:1-22.